Aquatic Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Aquatic Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.3M	Buy	+32,577	New	+$22.2M	0.7%	14
2025 Q4	–	Sell	-13,831	Closed	-$7.78M	–	1706
2025 Q3	$7.78M	Sell	13,831 -38,194	-73%	-$21.6M	0.14%	175
2025 Q2	$27.3M	Buy	52,025 +39,464	+314%	+$22M	0.55%	37
2025 Q1	$7.97M	Sell	12,561 -14,520	-54%	-$9.99M	0.2%	130
2024 Q4	$19.3M	Buy	27,081 +15,241	+129%	+$12.8M	0.52%	44
2024 Q3	$12.4M	Buy	+11,840	New	+$13.2M	0.33%	91
2024 Q1	–	Sell	-11,280	Closed	-$9.91M	–	1572
2023 Q4	$9.91M	Buy	+11,280	New	+$9.29M	0.25%	102
2023 Q2	–	Sell	-2,500	Closed	-$2.05M	–	1681
2023 Q1	$2.05M	Sell	2,500 -5,700	-70%	-$4.3M	0.13%	181
2022 Q4	$5.92M	Buy	+8,200	New	+$6.05M	0.43%	46
2022 Q1	–	Sell	-100	Closed	-$63K	–	1447
2021 Q4	$63K	Buy	+100	New	+$61.5K	0.12%	241

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Aquatic Capital Management's REGN Position: Q2 2026 in Review

Aquatic Capital Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 32,577 shares worth $20.3M. The stake represents 0.7% of the portfolio and ranks #14 among its holdings. This is a return to the name: Aquatic Capital Management previously reported a position in REGN as recently as Q3 2025.

Aquatic Capital Management first reported a position in REGN in Q4 2021 and has held it in 10 quarters since. The position peaked at $27.3M in Q2 2025. 1,338 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Aquatic Capital Management held 32,577 shares of Regeneron Pharmaceuticals worth $20.3M as of Q2 2026.
Regeneron Pharmaceuticals was a new Aquatic Capital Management position in Q2 2026.
Regeneron Pharmaceuticals made up 0.7% of Aquatic Capital Management's portfolio in Q2 2026, its #14 holding.
Aquatic Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2021 and has held it in 10 quarters since.
Aquatic Capital Management's Regeneron Pharmaceuticals position peaked at $27.3M in Q2 2025.
1,338 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.